Regulus Therapeutics Inc (NASDAQ:RGLS) shares were up 5.3% during mid-day trading on Monday . The stock traded as high as $0.96 and last traded at $0.90. Approximately 604,430 shares changed hands during trading, a decline of 7% from the average daily volume of 651,595 shares. The stock had previously closed at $0.95.
A number of research analysts have weighed in on RGLS shares. Zacks Investment Research lowered shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a research note on Tuesday, November 14th. Wedbush reaffirmed an “outperform” rating and issued a $4.00 price objective on shares of Regulus Therapeutics in a research note on Monday, December 11th. Leerink Swann started coverage on shares of Regulus Therapeutics in a research note on Friday, January 5th. They issued an “outperform” rating and a $2.00 price objective on the stock. Finally, BMO Capital Markets set a $1.00 price objective on shares of Regulus Therapeutics and gave the company a “hold” rating in a research note on Thursday, March 8th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $2.20.
The company has a market cap of $88.90, a price-to-earnings ratio of -1.18 and a beta of 1.71.
Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.03. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative net margin of 99,868.07% and a negative return on equity of 201.84%. sell-side analysts predict that Regulus Therapeutics Inc will post -0.64 EPS for the current year.
Hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. purchased a new stake in shares of Regulus Therapeutics in the third quarter valued at about $347,000. Goldman Sachs Group Inc. raised its holdings in shares of Regulus Therapeutics by 189.1% in the second quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 240,890 shares during the last quarter. Candriam Luxembourg S.C.A. purchased a new stake in shares of Regulus Therapeutics in the third quarter valued at about $750,000. BVF Inc. IL raised its holdings in shares of Regulus Therapeutics by 7.9% in the fourth quarter. BVF Inc. IL now owns 13,974,249 shares of the biopharmaceutical company’s stock valued at $14,533,000 after purchasing an additional 1,025,020 shares during the last quarter. Finally, South Dakota Investment Council raised its holdings in shares of Regulus Therapeutics by 37.1% in the third quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock valued at $2,275,000 after purchasing an additional 492,969 shares during the last quarter. Institutional investors own 53.72% of the company’s stock.
WARNING: “Regulus Therapeutics (RGLS) Trading Up -5.3%” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://ledgergazette.com/2018/03/14/regulus-therapeutics-rgls-trading-up-5-3.html.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.